Carboplatin plus weekly paclitaxel combined with bevacizumab as first-line treatment for non-small cell lung cancer

Anticancer Research

Volumn 37, Issue 2, 2017, Pages 923-928

  Yamasaki, Masahiro ^a   Murakami, Isao ^b   Nakano, Kikuo ^c   Doi, Mihoko ^d   Kitaguchi, Souichi ^e   Kondo, Tomohiro ^f   Sakurai, Joji ^g   Hattori, Noboru ^h   Arita, Ken Ichi ⁱ  

^a ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^b Saijo cho   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION   (Japan)

^d HIROSHIMA PREFECTURAL HOSPITAL   (Japan)

^e HIROSHIMA CITY ASA HOSPITAL   (Japan)

^f JA Hiroshima General Hospital   (Japan)

^g Sakurai Clinic   (Japan)

^h HIROSHIMA UNIVERSITY   (Japan)

ⁱ Mihara Red Cross Hospital   (Japan)

Author keywords

Bevacizumab; Carboplatin; Non squamous non small cell lung cancer; Phase II study; Weekly paclitaxel

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; BILIRUBIN; CARBOPLATIN; CREATININE; EPIDERMAL GROWTH FACTOR RECEPTOR; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENE MUTATION; GINGIVA BLEEDING; HEMORRHOID HEMORRHAGE; HUMAN; HYPERKALEMIA; HYPERTENSION; INDUCTION CHEMOTHERAPY; INFECTION; LEUKOPENIA; LUNG ADENOCARCINOMA; MAINTENANCE CHEMOTHERAPY; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OPEN STUDY; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PNEUMOTHORAX; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; CARCINOMA, NON-SMALL-CELL LUNG; CHEMICALLY INDUCED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DIARRHEA; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEBRILE NEUTROPENIA; FEMALE; HUMANS; INFECTION; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; TREATMENT OUTCOME; VOMITING;

EID: 85013635489     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: 10.21873/anticanres.11400     Document Type: Article

References (18)

1. Herbst RS, Heymach JV and Lippman SM: Lung cancer. N Engl J Med 359: 1367-1380, 2008.
2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J and Johnson DH: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98, 2002.
3. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y and Fukuoka M: Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18: 317-323, 2007.
4. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R and Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542-2550, 2006.
5. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N and Manegold C: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27: 1227-1234, 2009.
6. Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, Ahn MJ, Aerts JG, Gorbunova V, Vikstrom A, Wong EK, Perez-Moreno P, Mitchell L and Groen HJ: Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol 31: 3004-3011, 2013.
7. Niho S, Kunitoh H, Nokihara H, Horai T, Ichinose Y, Hida T, Yamamoto N, Kawahara M, Shinkai T, Nakagawa K, Matsui K, Negoro S, Yokoyama A, Kudoh S, Kiura K, Mori K, Okamoto H, Sakai H, Takeda K, Yokota S, Saijo N and Fukuoka M: Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer 76: 362-367, 2012.
8. Belani CP, Ramalingam S, Perry MC, LaRocca RV, Rinaldi D, Gable PS and Tester WJ: Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol 26: 468-473, 2008.
9. Sakakibara T, Inoue A, Sugawara S, Maemondo M, Ishida T, Usui K, Abe T, Kanbe M, Watanabe H, Saijo Y and Nukiwa T: Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small-cell lung cancer. Ann Oncol 21: 795-799, 2010.
10. Sobin L, Gospodarowicz MK and Wittekind C: Lung and Pleural tumors, TNM Classification of Malignant Tumours, Seventh Edition. Wiley-Blackwell, New York, pp. 136-150, 2009.
11. Ohashi N, Daga H, Nishino R, Mito A, Moritani C, Takakura R, Taooka K, Nakamura K, Daido K and Arita K: Phase I/II study of carboplatin and weekly paclitaxel for advanced non-small cell lung cancer. Haigan (JJLC) 44: 77-82, 2004 (in Japanese).
12. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events (CTCAE) v4.0, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc.htm
13. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
14. One Arm Binomial, Biostatistical Tools, Cancer Research And Biostatistics, https://stattools.crab.org/Calculators/oneArm BinomialColored.html
15. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R and Taraboletti G: The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2: 1843-1849, 1996.
16. Miller KD, Sweeney CJ and Sledge GW Jr.: Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 19: 1195-1206, 2001.
17. Jiang H, Tao W, Zhang M, Pan S, Kanwar JR and Sun X: Lowdose metronomic paclitaxel chemotherapy suppresses breast tumors and metastases in mice. Cancer Invest 28: 74-84, 2010.
18. Kubota T, Okano Y, Sakai M, Takaoka M, Tsukuda T, Anabuki K, Kawase S, Miyamoto S, Ohnishi H, Hatakeyama N, Machida H, Urata T, Yamamoto A, Ogushi F and Yokoyama A: Carboplatin plus weekly paclitaxel with bevacizumab for firstline treatment of non-small cell lung cancer. Anticancer Res 36: 307-312, 2016.